CytoSorbents announced that it has received the recommendation from the independent Data and Safety Monitoring Board to continue the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor trial as planned without any modifications.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTSO:
